Compare Amgen, Inc. (AMGN) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Cisco Systems Inc — how do they compare? Amgen, Inc. trades at $365.51 (market cap $196.12B), while Cisco Systems Inc trades at $120.55 (market cap $478.14B). The key difference: Cisco Systems Inc is far larger — about 2.4× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CSCO | |
|---|---|---|
Market Cap | $196.12B | $478.14B |
Sector | Health | Technology |
52-Week High | $388.16 | $130.00 |
52-Week Low | $271.18 | $66.20 |
Enterprise Value | $241.41B | $492.80B |
Dividend Yield | 2.77% | 1.38% |
Volume | — | 22,887,319 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Cisco Systems (CSCO) trades at $121.31, up 2.54% with a bullish technical signal. Recent earnings beats and strong AI cybersecurity partnerships drive momentum. The stock shows solid fundamentals with $56.65B revenue and 19.69% net margin, though valuation ratios like P/E of 40.44 appear elevated. Positive analyst sentiment includes a $130.38 consensus target.
Outlook remains positive with AI-driven growth opportunities, but risks include competitive pressures and high debt levels. The stock offers steady dividends and institutional support, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
